On July 22, 2022, ALD Connect will host an Externally-Led Patient-Focused Drug Development meeting to provide an opportunity for the Food and Drug Administration (FDA), industry partners, and other key stakeholders to hear directly from adults with ALD and their caregivers. They will explain the impact the disease has on their daily lives, what meaningful treatments would be, their experiences with currently available treatments, and their hopes for the future.
They are collecting comments from the ALD community. Comments will be included in the Voice of the Patient report. If you can spare a few minutes to leave a comment on your journey with ALD, they would much appreciate it!
or email: pfdd@aldconnect.org
Thanks!